Newsfeeds - Spark Newswire

2 minute read

Wesana Health One Step Closer To Clinical Trials Of Psilocybin And CBD Based Treatment Of Brain Injury Related MDD

Today, 8:09 AM

Wesana Health Holdings Inc. (OTCQB:WSNAF)â€¯(CSE:WESA) have received a full written response from the Food and Drug Administration regarding…

CSE:WESA

2 minute read

Researcher Portrayed In Hollywood Movie By Alec Baldwin Joins Psychedelics Company

By Natan Ponieman

Today, 8:09 AM

In 2015, the movie â€‹â€‹Concussion, starring Will Smith and Alec Baldwin, told the true story of a doctor and his fight…

BWVI

2 minute read

Psychedelics Biotech Companies Mark New Milestones In Drug Development Pipelines: Field Trip, Cybin and Wesana

By Natan Ponieman

Today, 8:09 AM

On Tuesday, three public companies in the psychedelics/biotech space announced significant milestones in their drug development pipelines.

CSE:WESA

3 minute read

The Legacy Of Dr. Aaron Beck, Father Of Cognitive Therapy, Lives On In Psychedelic Medicine

By Natan Ponieman

Today, 8:09 AM

Dr. Aaron T. Beck, the father of cognitive therapy, died on Monday at his home in Philadelphia at age 100.

CSE:WESA

6 minute read

Psyched: First Active Psychedelics ETF Hits NYSE, Compass Dives Into Novel Molecules, Atai Subsidiary Launches Phase 2a Trial

By Natan Ponieman

Today, 8:09 AM

AdvisorShares Launches First NYSE-listed Actively-managed Psychedelics ETF On Thursday, AdvisorShares launched the country’s first actively managed ETF covering the psychedelics sector.

ATAI

2 minute read

Can MDMA Treat Traumatic Brain Injury? $1.5 Million Are Being Committed To Finding Out

By Natan Ponieman

Today, 8:09 AM

Wesana Health (CSE: WESA) (OTCQB: WSNAF) and the Multidisciplinary Association for Psychedelic Studies (MAPS) are teaming up to analyze the effectiveness of MDMA-assisted therapy in the treatment of traumatic brain injury (TBI).

CSE:WESA

7 minute read

Meet The Top 12 CEOs In The Psychedelics Industry

By Natan Ponieman

Today, 8:09 AM

By Natan Ponieman and Javier Hasse The psychedelic medicine industry is growing by leaps and bounds. Leading this charge is a group of ambitious and visionary corporate leaders, working to create new methods for the treatment of mental health and other serious conditions.

ATAI

4 minute read

Psyched: Atai Launches ‘Salvia Divinorum’ Subsidiary, Mindset, Psilera and Wesana’s Preclinical Trials, Origin Raises $5M

By Natan Ponieman

Today, 8:09 AM

Atai Life Sciences Launches New Salvia Divinorum Subsidiary Atai Life Sciences (NASDAQ: ATAI) announced the launch of a new subsidiary that will research Salvinorin A, the active compound in salvia divinorum, a hallucinogenic herb native to Central America.

ATAI

5 minute read

Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies

By Natan Ponieman

Today, 8:09 AM

Irish 5-MeO-DMT Company GH Research Debuts On Nasdaq GH Research, a Dublin-based company studying the potential of 5-MeO-DMT for the treatment of psychiatric and neurological disorders, is now listing its stock on the Nasdaq under the symbol “GHRS.”

BRAXF